1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442.
3. Aalders JG, Thomas G. Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. Gynecol Oncol. 2007;104(1):222-31.
4. Loeb S, Partin AW, Schaeffer EM. Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol. 2010;12(1):20-4.
6. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer.
Cochrane Database Syst Rev. 2010;(1):CD007585. doi: 10.1002/14651858.CD007585.pub2.
7. Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer.
Gynecol Oncol. 1998;71(3):340-3.
8. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma.
Obstet Gynecol. 2000;95(5):692-6.
9. Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
Gynecol Oncol. 2004;95(3):546-51.
10. Manfredi R, Mirk P, Maresca G, Margariti PA, Testa A, Zannoni GF, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231(2):372-8.
11. Moore R, Brown A, Miller C, Badgwell D, Lu Z, Verch T, et al. Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer.
Gynecol Oncol. 2008;110(2):196-201. doi: 10.1016/j.ygyno.2008.04.002.
12. Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus.
Int J Gynecol Cancer. 2011;21(7):1185-90. doi: 10.1097/IGC.0b013e3182229ad8.
13. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.
Tumour Biol. 2013;34(1):571-6. doi: 10.1007/s13277-012-0583-0.
14. Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.
Gynecol Oncol. 2012;124(2):270-5. doi: 10.1016/j.ygyno.2011.10.025.
15. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.
Br J Cancer. 2011;104(9):1418-25. doi: 10.1038/bjc.2011.109.
16. Frederick PJ, Straughn Jr JM. The role of comprehensive surgical staging in patients with endometrial cancer.
Cancer Control. 2009;16(1):23-9.
17. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.
Biol Reprod. 1991;45(2):350-7.
18. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.
Br J Cancer. 2009;100(8):1315-9. doi: 10.1038/sj.bjc.6605011.
19. Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32(6):1087-95. doi: 10.1007/s13277-011-0204-3.
20. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.
Am J Obstet Gynecol. 2012;206(4):351.e1-8. doi: 10.1016/j.ajog.2011.12.029.
21. Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer—a population based study.
Gynecol Oncol. 2014;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036.
22. Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Acta Obstet Gynecol Scand. 2013;92(11):1313-22. doi: 10.1111/aogs.12235.
23. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients.
Gynecol Oncol. 2012;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022.